In recent years, SPX has been implicated in mood/behavioral disorders and other metabolic diseases (29, 30), and emerged as a new target for drug development, e.g., for SPX-based GalR2 analogs with anxiolytic/antidepressive activity (31) but reduced propensity for receptor desensitization (32). This evidence concerns the gene SPX and metabolic disease.